Dr Youssouf is an alumnus of Imperial College London (MSc Human Molecular Genetics 2008; PhD Statistical Genetics 2012), where she started her career in clinical research, overseeing breast cancer drug trials. She moved to the London School of Hygiene and Tropical Medicine in 2015 where she managed several trials including the CRASH trials (use of tranexamic acid in patients with TBI) and the AMBITION-cm trial which prompted her relocation to Botswana in 2017. Since the completion of the AMBITION-cm trial, Nabila joined Professor Mosepele’s research group as its Research Program Manager where she holds a hybrid role, 1. Performing administrative, financial and regulatory duties, mainly on the InterCARE trial (integration of CVD care within existing HIV services) and the WHO Solidarity PLUS trial (RCT of additional treatments for COVID-19 in hospitalised patients who are all receiving the local SoC), and 2. Leading research projects as principal investigator and developing proposals. Her interests include public engagement; implementation science methodology and COVID-19 related impact on healthcare systems and clinical research. She was recently awarded an early-stage investigator grant through the NIH/NHLBI to investigate the effects of the pandemic on 6 implementation science research projects in sub-Saharan Africa. Nabila was elected to the United Kingdom Trial Managers Network (UKTMN) Executive Board in September 2021 to lead its professional development strategy and trial management competency groups. Nabila is an active educator with teaching positions on the distance learning Infectious Diseases program and the newly established course on Pandemic Preparedness Response & Research, both at the London School of Hygiene and Tropical Medicine.